The pharmaceutical industry’s biggest lobbying group is scheduled to meet with President Donald Trump on Thursday, according ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

The best way to beat persistent inflation is to invest in businesses unaffected by rising prices, like these four high-yield ...

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Buy low, sell high. That has been a good strategy for investors for a long time. However, finding great stocks to buy under ...

Claims on social media suggest Pfizer's COVID vaccine has fatal side effects, referencing a US House document. However, the ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

The Pentagon says the military services must again ask troops who were forced out or who voluntarily left the military due to ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...